Stockholm, Sweden, December 9, 2003 Gambro AB (Stockholmsbörsen:
GAMBaST, GAMBbST), a leading international medical technology and
healthcare company, today announced that its subsidiary Gambro BCT has
received approval from the Japanese Red Cross for its automated blood
collection system for collection of leukoreduced platelets and plasma.
The approval of the Trima Accel System represents a major milestone for
Gambro BCT on the Japanese market.

During the autumn of 2003, marketing trials were conducted in four blood
centers throughout Japan. After evaluation, the Japanese Red Cross found
the performance of the system met and exceeded expectations. Blood
center operators found it easy to use and donor friendly.

70% of platelet collections in Japan are collections with a lower yield
of platelets than are typical for other areas of the world. The majority
of donors in Japan are small in size, which means they...